153 related articles for article (PubMed ID: 38186883)
1. Urinary matrix metalloproteinase-7 is a sensitive biomarker to evaluate renal tubular injury in patients with minimal change disease and focal segmental glomerulosclerosis.
Yin DY; Hou GL; Yang XQ; Bi LL; Mei XF; Bai MK; Zhou L; Zhu S; Huang YJ
Clin Kidney J; 2024 Jan; 17(1):sfad027. PubMed ID: 38186883
[TBL] [Abstract][Full Text] [Related]
2. Urine MMP7 as a kidney injury biomarker.
Avello A; Guerrero-Mauvecin J; Sanz AB
Clin Kidney J; 2024 Jan; 17(1):sfad233. PubMed ID: 38186894
[TBL] [Abstract][Full Text] [Related]
3. Urinary soluble HLA class I antigen in patients with minimal change disease: a predictor of steroid response.
Park CW; Song HC; Shin YS; Ahn SJ; Kim YS; Kim SY; Choi EJ; Chang YS; Bang BK
Nephron; 1998; 79(1):44-9. PubMed ID: 9609461
[TBL] [Abstract][Full Text] [Related]
4. Urinary N-acetyl-beta-glucosaminidase excretion is a marker of tubular cell dysfunction and a predictor of outcome in primary glomerulonephritis.
Bazzi C; Petrini C; Rizza V; Arrigo G; Napodano P; Paparella M; D'Amico G
Nephrol Dial Transplant; 2002 Nov; 17(11):1890-6. PubMed ID: 12401843
[TBL] [Abstract][Full Text] [Related]
5. Comparative differential proteomic analysis of minimal change disease and focal segmental glomerulosclerosis.
Pérez V; López D; Boixadera E; Ibernón M; Espinal A; Bonet J; Romero R
BMC Nephrol; 2017 Feb; 18(1):49. PubMed ID: 28158993
[TBL] [Abstract][Full Text] [Related]
6. A Prospective Study on Complement Activation Distinguishes Focal Segmental Glomerulosclerosis from Minimal Change Disease.
Cambier A; Patey N; Royal V; Gougeon F; Genest DS; Brachemi S; Bollée G; Merlen C; Bonnefoy A; Lapeyraque AL; Troyanov S
Kidney Int Rep; 2024 Mar; 9(3):661-670. PubMed ID: 38481495
[TBL] [Abstract][Full Text] [Related]
7. Circulating and urinary microRNA profile in focal segmental glomerulosclerosis: a pilot study.
Ramezani A; Devaney JM; Cohen S; Wing MR; Scott R; Knoblach S; Singhal R; Howard L; Kopp JB; Raj DS
Eur J Clin Invest; 2015 Apr; 45(4):394-404. PubMed ID: 25682967
[TBL] [Abstract][Full Text] [Related]
8. Urinary proteins from patients with nephrotic syndrome alters the signalling proteins regulating epithelial-mesenchymal transition.
Wen Q; Huang Z; Zhou SF; Li XY; Luo N; Yu XQ
Nephrology (Carlton); 2010 Feb; 15(1):63-74. PubMed ID: 20377773
[TBL] [Abstract][Full Text] [Related]
9. Immunoglobulin G/albumin staining in tubular protein reabsorption droplets in minimal change disease and focal segmental glomerulosclerosis.
Bu L; Mirocha J; Haas M
Nephrol Dial Transplant; 2021 May; 36(6):1016-1022. PubMed ID: 32191308
[TBL] [Abstract][Full Text] [Related]
10. Urinary fibrinogen and renal tubulointerstitial fibrinogen deposition: Discriminating between primary FSGS and minimal change disease.
Wang Y; Zheng C; Xu F; Liu Z
Biochem Biophys Res Commun; 2016 Sep; 478(3):1147-52. PubMed ID: 27539323
[TBL] [Abstract][Full Text] [Related]
11. CD80 and suPAR in patients with minimal change disease and focal segmental glomerulosclerosis: diagnostic and pathogenic significance.
Cara-Fuentes G; Wei C; Segarra A; Ishimoto T; Rivard C; Johnson RJ; Reiser J; Garin EH
Pediatr Nephrol; 2014 Aug; 29(8):1363-71. PubMed ID: 24263531
[TBL] [Abstract][Full Text] [Related]
12. Potential Urine Proteomic Biomarkers for Focal Segmental Glomerulosclerosis and Minimal Change Disease.
Chebotareva NV; Vinogradov A; Brzhozovskiy AG; Kashirina DN; Indeykina MI; Bugrova AE; Lebedeva M; Moiseev S; Nikolaev EN; Kononikhin AS
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293475
[TBL] [Abstract][Full Text] [Related]
13. Urinary CD80 is elevated in minimal change disease but not in focal segmental glomerulosclerosis.
Garin EH; Mu W; Arthur JM; Rivard CJ; Araya CE; Shimada M; Johnson RJ
Kidney Int; 2010 Aug; 78(3):296-302. PubMed ID: 20485332
[TBL] [Abstract][Full Text] [Related]
14. Differential chemokine expression in tubular cells in response to urinary proteins from patients with nephrotic syndrome.
Huang Z; Wen Q; Zhou SF; Yu XQ
Cytokine; 2008 May; 42(2):222-233. PubMed ID: 18362077
[TBL] [Abstract][Full Text] [Related]
15. Minimal change disease and idiopathic focal segmental glomerulosclerosis in adults. A quantitative study.
Danilewicz M; Wagrowska-Danilewicz M
Pol J Pathol; 1996; 47(4):209-14. PubMed ID: 9097714
[TBL] [Abstract][Full Text] [Related]
16. Urinary MMP-9/NGAL ratio as a potential marker of FSGS in nephrotic children.
Korzeniecka-Kozerska A; Wasilewska A; Tenderenda E; Sulik A; Cybulski K
Dis Markers; 2013; 34(5):357-62. PubMed ID: 23478276
[TBL] [Abstract][Full Text] [Related]
17. In situ evaluation of podocytes in patients with focal segmental glomerulosclerosis and minimal change disease.
da Silva CA; Monteiro MLGDR; Araújo LS; Urzedo MG; Rocha LB; Dos Reis MA; Machado JR
PLoS One; 2020; 15(11):e0241745. PubMed ID: 33147279
[TBL] [Abstract][Full Text] [Related]
18. [Effect of Mild Moxibustion with Different Terms at Different Acupoints on Renal Functions and Renal Pathological Changes in Focal Segmental Glomerulosclerosis Rats].
Li L; Sun YX; Ma JY; Zhang CL; Li Y
Zhen Ci Yan Jiu; 2016 Dec; 41(6):521-7. PubMed ID: 29071895
[TBL] [Abstract][Full Text] [Related]
19. Messenger RNA expression of B7-1 and NPHS1 in urinary sediment could be useful to differentiate between minimal-change disease and focal segmental glomerulosclerosis in adult patients.
Navarro-Muñoz M; Ibernon M; Pérez V; Ara J; Espinal A; López D; Bonet J; Romero R
Nephrol Dial Transplant; 2011 Dec; 26(12):3914-23. PubMed ID: 21414970
[TBL] [Abstract][Full Text] [Related]
20. Synaptopodin immunoexpression in steroid-responsive and steroid-resistant minimal change disease and focal segmental glomerulosclerosis.
Wagrowska-Danilewicz M; Danilewicz M
Nefrologia; 2007; 27(6):710-5. PubMed ID: 18336100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
